Comparative Pharmacology
Head-to-head clinical analysis: VANTAS versus VIADUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANTAS versus VIADUR.
VANTAS vs VIADUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist; continuous stimulation suppresses pituitary gonadotropin secretion, resulting in decreased testosterone production.
Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist that stimulates pituitary gonadotropin release initially, followed by sustained suppression of pituitary gonadotropins due to receptor desensitization, leading to reduced testosterone production.
10 mg subcutaneously every 24 weeks.
Leuprolide acetate implant 65 mg implanted subcutaneously in the inner aspect of the upper arm once yearly.
None Documented
None Documented
Terminal elimination half-life approximately 4 weeks (28 days) due to continuous release from the implant; after implant removal, plasma concentrations decline with a half-life of about 3-4 days.
The terminal elimination half-life of leuprolide acetate following subcutaneous administration is approximately 3 hours. In patients with renal impairment, half-life may be prolonged; however, no dose adjustment is recommended for mild-to-moderate impairment.
Renal: negligible. Fecal: ~100% (unchanged drug). Histrelin is not metabolized and is excreted unchanged in feces via biliary elimination.
Leuprolide acetate is primarily eliminated via hepatic metabolism and renal excretion. Approximately 48% of the dose is recovered in urine over 24 hours, with 5% as unchanged drug. Fecal excretion accounts for about 5%.
Category C
Category C
GnRH Agonist
GnRH Agonist